New drug combo after transplant aims to stop leukemia relapse and graft-versus-host disease
NCT ID NCT07548983
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This early-phase study tests whether giving two drugs—ruxolitinib and azacitidine—after a stem cell transplant can safely prevent graft-versus-host disease (GVHD) and keep acute myeloid leukemia (AML) from coming back. About 40 adults with AML in remission will receive ruxolitinib alone first, then both drugs together. The main goal is to find the best dose and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a targeted drug plus donor immune cells fight back against relapsed leukemia?
- Can a Two-Drug combo outsmart a deadly leukemia?
- Can a new pill take on Hard-to-Treat leukemia?
- Leukemia drug cocktail aims to boost remission in High-Risk patients
- Could bone marrow from deceased donors cure blood cancers?